Loading...

Follow Arthritis Broadcast Network - News on Feedspot

Continue with Google
Continue with Facebook
or

Valid

Do you know a person with arthritis who has, or is, providing leadership in the community and deserves recognition for their valuable volunteer work? We encourage you to help us celebrate their contributions by nominating them for the Qualman-Davies Arthritis Consumer Community Leadership Award. 

To submit a nomination, please follow the steps listed below:

  1. Obtain the prospective nominee’s consent to be nominated prior to submitting this form
  2. Click here for the nomination form. If you create a separate nomination document, please use the headings provided on the Nomination Form PDF for ease of review by the award adjudication committee.
  3. Provide the completed nomination form to the nominee for their review for accuracy and obtain their signature on the document
  4. Submit the form to feedback@jointhealth.org

The application deadline is September 27, 2019. Each submission will be reviewed by the award adjudication committee and scored using a points system. The winner and their nominator will be notified by October 9, 2019. The award will be bestowed in person at the Arthritis Alliance of Canada Annual Meeting’s Luncheon and Special Award Ceremony taking place on Friday, November 29, 2019 in Toronto, Ontario.

  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

Biosimilars: The next generation of biologic treatment for inflammatory arthritis patients 

In this issue of JointHealth insight, we provide patients with inflammatory arthritis important facts to help them understand biosimilars and have an informed conversation with their healthcare provider.

Topics covered in this issue include:

What are biologic biosimilars?

Biologics are life-saving “advanced therapy” treatments – meaning they are used after conventional disease modifying anti-rheumatic drugs (csDMARDs), such as methotrexate, hydroxychloroquine and sulfasalazine – that can help patients with inflammatory forms of arthritis. They are made from complex large molecules that come from living cells. Biologics are time consuming to research, develop and manufacture, making them expensive when they first come into the market place as a patented medicine. This can limit patients’ reimbursement access to such medicines and can make it difficult for the health care system to afford them.

Biosimilars are the next generation of biologic treatment and have nearly the same effectiveness, safety, immunogenicity profile and quality and deliver the same therapeutic benefits to patients as their originator; in some studies, slightly better.

After meeting Health Canada’s strict safety and efficacy requirements, biosimilars enter the market after a biologic originator patent expires, just like a small molecule generic medication does when the brand name medication’s patent expires. And just as generic medications are much lower in price compared to their original versions, so too are biosimilars. 

For example:

  • etanercept (Brenzys®) and etanercept (Erelzi®) are biologic biosimilar versions of the biologic originator etanercept (Enbrel®);
  • infliximab-Inflectra® and infliximab-Renflexis® are biologic biosimilar versions of the biologic originator infliximab-Remicade®).

Biosimilars have been approved for use in Canada since 2009, and in inflammatory arthritis since 2014 – there are more biologic originators and biosimilars in use in inflammatory arthritis than in any other disease.

The European Medicines Agency has published a guide to provide healthcare professionals with information on the science and regulation underpinning the use of biosimilars: “Over the last 10 years, the EU monitoring system for safety concerns has not identified any relevant difference in the nature, severity or frequency of adverse effects between 28 biosimilars and their reference medicines.

Since the European Union (EU) approved the first biosimilar in 2006, it has approved the highest number of biosimilars worldwide, gaining experience of their use and safety. During this period, the EU monitoring system for safety concerns has not identified any relevant difference in the nature, severity or frequency of adverse effects between biosimilars and their biologic originators.

Read more: JointHealth insight

  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

Does your workplace deserve to be recognized for their best arthritis practices? Nominate them by August 9, 2019

Canadian employers, working with their private health insurers, are increasingly looking for ways to promote patient-focused prevention, treatment and management of arthritis as part of a health and wellness program for employees. To recognize these best arthritis practices, Arthritis Consumer Experts (ACE) announces the search for Canada’s Best Workplaces for Employees Living with Arthritis. 

ACE analyzes company practices and programs compared to other nominated companies. The judging criteria this year will focus on:

  • flexible work arrangements that meet the needs of employees living with arthritis to manage their disease and work with symptoms such as pain, fatigue, joint dysfunction or immobility; and,
  • employer benefit plans, particularly drug plans that help people with arthritis gain access to life-saving medications they and their doctors have decided they need.

To nominate your company for Canada’s Best Workplaces for Employees Living with Arthritis award, please click here. The deadline to apply is August 9, 2019. Please submit your nominations to feedback@jointhealth.org.

  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

Fatigue is a common, persistent problem for rheumatoid arthritis (RA) patients. Affecting 40% – 80% of RA patients, fatigue is considered one of the most important disease outcomes by patients. Work disability is among the most important consequences of RA-related fatigue. According to Professor Jose Antonio da Silva, patients have identified fatigue as the principal barrier to employment and productivity.

In a special EULAR session, Professor da Silva noted that numerous studies have demonstrated that fatigue in RA contributes to a higher likelihood of absenteeism at work, a higher prevalence of the various dimensions of work disability, and more consultations with physicians and referrals to therapists. A challenge for rheumatologists is determining how to measure fatigue in RA where there is no consensus on the most effective method of measurement and lack of a standardized assessment tool. Professor da Silva added that overall, the measurement of fatigue in RA entails several challenges because of its subjective nature.

To learn more about arthritis in the Canadian workforce and an upcoming program to support employees with arthritis, read this issue of JointHealth insight.

Global RA Network meeting at EULAR Did you know?

Arthritis Consumer Experts (ACE) is a founding member and serves as the Secretariat of the Global RA Network. The Network was formed to build international relationships and identify and work on common goals and initiatives to improve the lives of people living with RA around the world.

During the EULAR conference, ACE led a meeting of the Network, attended by leaders from 13 different member countries. At the meeting, ACE introduced new tools that have been developed for the Global RA Network website, including the RA models of Care Pathway Toolkit, and RA Communiqué.

  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

At a EULAR session titled “Bringing Digital Healthcare Solutions to Patients,” attendees learned how e-health tools, such as online and mobile apps, can enhance treatment and redefine the patient-rheumatologist relationship. Dr. Paul Studenic from the Medical University of Vienna told his audience:

“On-line platforms can be used to share information among patients to foster peer support as well as theexchange between patients and healthcare professionals. E-health opportunities will set new standards for patient education and for improved adherence.”

He also noted the transition from paper-based records to electronic medical records not only allows health professionals a more comprehensive view of patient history and outcomes, but also provides patients the option to browse their own medical records remotely. 

Some mobile apps allow patients to track daily symptoms of their arthritis in between appointments. “The integration of patient-generated data in between medical visits by the use of mobile apps is of particular importance in the case of chronic diseases to better depict how well individuals with arthritis are doing and for the identification of flares that may require earlier clinical consultations than previously appointed with a patient,” said Dr. Studenic.

ACE has developed several on-line resources for patients as well as two of North America’s most comprehensive mobile arthritis apps designed for patients and healthcare professionals. The apps feature the most current, evidence-based arthritis information to help detect, treat and manage arthritis. Please click here to learn more about ACE’s apps ArthritisID and ArthritisID Pro. The apps are available on iPhone and iPad:

The Arthritis Screening Exam, a key component of the apps, is available online:

  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

Madrid is the host for the 20th Annual EULAR Congress of Rheumatology. More than 14,000 participants from more than 120 countries will hear from more than 500 speakers and choose from approximately 2,500 abstract presentations. 

Weight loss benefits for psoriatic arthritis patients

On the first day, attendees heard a presentation on the potential for weight loss to improve outcomes in patients with psoriatic arthritis (PsA). According to Dr. Stefan Siebert of the Institute of Infection, Immunity and Inflammation at the University of Glasgow: “There are multiple sets of data that show obesity predicts who develops PsA. Our data further show that, of patients with PsA who are candidates for a biologic, those with obesity have greater disease activity.” Dr. Siebart added: “We are using all of these expensive drugs, but I think there is now a need to also focus on lifestyle interventions, in addition to drug therapy, to reduce disease activity and improve outcomes in PsA.”

Arthritis Consumer Experts (ACE) has multiple resources to help patients learn more about the benefits of a weight loss program, nutrition and exercise. All of these programs have been shown to substantially reduce the burden of joint disease in addition to the other health advantages of losing weight and eating well. To learn more, please visit the following resources on the ACE page:

ACE will be launching a new course on psoriatic arthritis as part of its JointHealth Education (JHEd) program.

JointHealth Education is specifically designed for the person recently diagnosed with arthritis or living with it for a while. This education program is based on the latest research and helps patients go from being a “student” of arthritis to a full-fledged “graduate” and helps them become a leader of their health care team. 

Click here to receive an email alert when the JHEd: PsA course goes live. You can sign up for our other JHEd courses here: https://info.jointhealth.org/jhed-landing-page

Treat to target in axial spondyloarthritis (axSpA)

Treat to target is an emerging management strategy in axial spondyloarthritis. This type of disease management is well established with patients with rheumatoid arthritis and psoriatic arthritis where you have a very specific target that you want to achieve. Whether or not the approach can also work in axSpA is open to debate. One of the issues is determining what should be measured and what is the appropriate target? At a Clinical Science Session at EULAR, Dr. Pedro Machado of University College London said studies have shown that “achieving inactive disease through treat to target strategies may improve structural outcomes and stop the development of radiographic damage of the spine.” Dr. Machado added that studies show that achieving inactive disease may also help to improve patients’ functional outcomes and quality of life.

Have you been diagnosed with ankylosing spondylitis (AS) or do you know someone who is living with it? ACE will be launching a new course in its JointHealth Education program focusing on AS. The course will help you learn about the disease, its treatment and how to have a positive, informed conversation with your rheumatologist of other members of your healthcare team.

JointHealth Education is specifically designed for the person recently diagnosed with arthritis or living with it for a while. This education program is based on the latest research and helps patients go from being a “student” of arthritis to a full-fledged “graduate” and helps them become a leader of their health care team. 

Click here to receive an email alert when the JHEd: AS course goes live. You can sign up for our other JHEd courses here: https://info.jointhealth.org/jhed-landing-page

  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

BC PharmaCare has recently added ixekizumab (Taltz®) to its provincial formulary for the treatment of psoriatic arthritis. 

Ixekizumab is approved by Health Canada for the treatment of psoriatic arthritis and will be reimbursed according to criteria detailed in HLTH 5360 (Initial/Switch) or HLTH 5361 (renewal), and when prescribed by a rheumatologist. BCPharmaCare covers a maximum 28-day supply of ixekizumab per fill. Click here to read the limited coverage drugs listing.

Ixekizumab is an inhibitor of interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in the inflammation associated with psoriasis, psoriatic arthritis, and some other inflammatory conditions. Ixekizumab has also been authorized for use in patients with moderate to severe plaque psoriasis.

  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

The government of British Columbia today announced the launch of the Biosimilars Initiative, which will implement new reimbursement coverage for patients on infliximab or etanercept for rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis. 

Between May 27, 2019 and November 22, 2019, patients on Remicade® will be transitioned to its biosimilar, either infliximab-Inflectra® or infliximab-Renflexis®. 

Over the six month period, reimbursement coverage will be provided for all originator and biosimilar brands, in order to provide time for patients to speak with their rheumatologist about transitioning to a biosimilar. 

Where can patients get more information about biosimilars?

There are several places patients can go for biosimilars information and support, including:

  • Your rheumatologist or rheumatology nurse or support staff
  • Biologic patient support program
  • Public or private drug formulary web sites

Arthritis Consumer Experts (ACE) has been a leader in biosimilars discussions since 2009, sharing information with stakeholders across Canada through free research-based workshops, webinars and education programs. Drawing from this experience, ACE has created the Biosim•Exchange (http://bit.ly/BiosimExchangeEN), an information hub for consumers to get the latest biosimilars news and background analysis. 

ACE has produced a special biosimilars education video series, where ACE speaks to medical experts on key patient questions around biosimilars and transitioning from originators to biosimilars: Go to https://biosim.jointhealth.org/resources and click on “Biosimilars education videos.”

ACE has recently published a new guide – “Biosimilars in Canada: What inflammatory arthritis patients need to know” – to address those needs of patients who want information on biosimilar medicines. It aims to provide answers to questions patients may have on biosimilars and provide them the information tools they need to power and support their conversations with their rheumatologists and other health care providers and ensure science-based continuity of care. Click on the following link to view the guide: https://jointhealth.org/pdfs/BiosimilarsInCanadaGuide_EN.pdf.

  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 
Vote4Arthritis: Responses to ACE’s arthritis survey

What changes would you like to see in models of arthritis care? 

ACE sent an open letter and a survey to candidates running in the Newfoundland and Labrador election. As part of its core government outreach activities and in the spirit of non-partisanship, ACE outlines the impact of arthritis in Newfoundland and Labrador and asks each candidate to share how government can improve prevention, treatment and care in Newfoundland and Labrador.

Below are the responses collected to date:

ACE letter sent to each candidate included:

Party responses to survey

Individual Candidate Responses

Please continue checking our Newfoundland and Labrador 2019 page as responses will be posted as we receive them. If you have comments, questions, or concerns about any of the answers provided, please take the time to contact the parties.

  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

The general election in Newfoundland and Labrador is scheduled for May 16, 2019. What changes would you like to see in arthritis models of care?

Arthritis is a chronic disease that has a devastating and debilitating effect on the lives of more than 115,000 Newfoundland and Labrador residents – approximately one in five. Within a generation, more than one in four residents are expected to have the most disabling and life-threatening types – osteoarthritis and rheumatoid arthritis.

Arthritis is also the leading cause of disability and work disability in Newfoundland and Labrador, with nearly three out of every five people with arthritis of working age.

Considering the prevalence of the disease and its significant cost to individuals and society, arthritis is an issue of great importance to candidates running for office. ACE sent an open letter and a survey to candidates running in the Newfoundland and Labrador election. As part of its core government outreach activities and in the spirit of non-partisanship, ACE asks each candidate to share how government can improve prevention, treatment and care in Newfoundland and Labrador.

The questionnaire asked the following questions:

  • What will your government do to bring a high quality, standardized evidence-based model of arthritis care for all Newfoundland and Labrador residents?
  • What will your government do to introduce patient education and exercise programs, such as GLA:D, that have been proven to significantly reduce hip or knee osteoarthritis symptoms?
  • What will your government do to improve the uptake of biosimilars and increase accessibility to life saving medications and reduce out-of-pocket costs for Newfoundland and Labrador residents living with inflammatory arthritis?
  • What will your government do to improve the healthcare and lives of Aboriginals living with arthritis in Newfoundland and Labrador?
  • How will your government establish better prevention programs and facilitate flexible work arrangements to help reduce the direct and indirect costs of arthritis to Newfoundland and Labrador employers and the provincial economy?
  • Will your government take steps to increase the number of rheumatologists and trained arthritis professionals to ensure timely, specialized care for Newfoundland and Labrador patients with arthritis?

ACE will be collecting Party and individual candidate’s responses. Responses will be posted on the Newfoundland and Labrador Election 2019 page as we receive them.

If you have comments, questions, or concerns about any of the answers provided, please take the time to contact the parties.

Did their responses help you decide how you will vote? Tell us what you think of their answers. Please contact us by .

Read for later

Articles marked as Favorite are saved for later viewing.
close
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

Separate tags by commas
To access this feature, please upgrade your account.
Start your free month
Free Preview